Indications for Non-Invasive Ventilation

Primary Indications by Clinical Scenario

• The European Respiratory Society recommends that either BiPAP or CPAP is strongly recommended for patients with acute respiratory failure due to cardiogenic pulmonary edema who remain hypoxic despite maximal medical treatment 2, 3
• Both BiPAP and CPAP decrease mortality (RR 0.80) and reduce intubation rates (RR 0.60) with moderate certainty of evidence in patients with cardiogenic pulmonary edema 2
• The European Respiratory Society suggests that CPAP offers advantages of simpler technology, easier synchronization, and potentially less expensive equipment 2
• BiPAP should be reserved for patients in whom CPAP is unsuccessful in the cardiogenic pulmonary edema setting 3
• Pre-hospital CPAP or BiPAP is conditionally recommended and decreases intubation rates (RR 0.31) in patients with cardiogenic pulmonary edema 2
• The European Respiratory Society indicates that BiPAP should be considered when respiratory acidosis (pH <7.35) persists despite maximum medical treatment on controlled oxygen therapy in patients with COPD exacerbations 5, 3
• This represents a strong indication with high-quality evidence (Grade A recommendation) for BiPAP in COPD exacerbations 5
• The American Thoracic Society recommends that BiPAP is specifically indicated for type 2 respiratory failure with elevated PaCO₂ in patients with COPD exacerbations 5
• The European Respiratory Society recommends that NIV (BiPAP or CPAP) is conditionally recommended for post-operative acute respiratory failure, particularly after thoracic or abdominal surgery 1, 7
• NIV reduces mortality (RR 0.28), intubation rates (RR 0.27), and nosocomial pneumonia (RR 0.20) in post-operative patients 7
• CPAP specifically decreased re-intubation rates from 10% to 1% after abdominal surgery in patients who developed hypoxemia immediately after extubation 7
• The European Respiratory Society suggests that a trial of NIV may be offered only in highly selected cooperative patients with isolated respiratory failure, managed by experienced teams in ICU settings 1
• Evidence shows reduced intubation rates (RR 0.75) but not mortality benefit, with low certainty of evidence for NIV in hypoxemic respiratory failure 1
• The European Respiratory Society indicates that BiPAP is indicated for acute or acute-on-chronic hypercapnic respiratory failure due to chest wall deformity or neuromuscular disease 5, 3
• BiPAP is specifically recommended for patients with neuromuscular disorders affecting respiratory function, particularly those requiring backup rate support 5

Initial Settings and Monitoring

• The European Respiratory Society recommends that minimum starting IPAP is 8 cm H₂O and minimum starting EPAP is 4 cm H₂O for BiPAP 4, 6
• Typical pressure differential is 4-6 cm H₂O (minimum 4 cm H₂O, maximum 10 cm H₂O) for BiPAP 4, 6
• The European Respiratory Society suggests that reassess early after starting NIV and intubate promptly if not improving 1
• Do not delay intubation if BiPAP fails to improve clinical status within 1-2 hours 4
• Monitor SpO₂ continuously, targeting 90-96% (or ≥92% in some guidelines) 4
• Repeat blood gases at 30-60 minutes after initiating BiPAP in hypercapnic patients 6

Absolute Contraindications

• The European Respiratory Society recommends that NIV should not be used in patients with recent facial or upper airway surgery 5, 7
• NIV should not be used in patients with facial burns or trauma 5
• NIV should not be used in patients with fixed upper airway obstruction 6
• NIV should not be used in patients with active vomiting 7
• NIV should not be used in patients with inability to protect the airway 3
• NIV should not be used in patients with copious respiratory secretions 5
• NIV should not be used in patients with life-threatening hypoxemia 7
• NIV should not be used in patients with severe confusion/agitation 6
• NIV should not be used in patients with recent upper gastrointestinal surgery 7
• NIV should not be used in patients with bowel obstruction 7